NovoCure (NVCR) Cash from Investing Activities Growth (5y) (2019 - 2026)
NovoCure (NVCR) Cash from Investing Activities Growth (5y) (2019 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 198.81 Bn | 193.21 Bn | 7.27 Bn |
| 2 | Stryker | 127.76 Bn | 124.28 Bn | 4.50 Bn |
| 3 | Medtronic | 118.77 Bn | 109.55 Bn | 6.41 Bn |
| 4 | Boston Scientific | 73.25 Bn | 72.71 Bn | 3.85 Bn |
| 5 | Edwards Lifesciences | 51.93 Bn | 47.68 Bn | 1.35 Bn |
| 6 | Dexcom | 34.43 Bn | 32.49 Bn | 830.00 Mn |
| 7 | GE HealthCare Technologies | 33.88 Bn | 31.77 Bn | 2.18 Bn |
| 8 | Koninklijke Philips | 26.35 Bn | 23.03 Bn | 4.55 Bn |
| 9 | Steris | 23.11 Bn | 22.63 Bn | 684.20 Mn |
| 10 | NovoCure | 2.03 Bn | 1.59 Bn | 142.48 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -19.49% |
| Mar 31, 2026 | -32.22% |
| Dec 31, 2025 | 20.57% |
| Sep 30, 2025 | -13.47% |
| Jun 30, 2025 | 66.65% |
| Mar 31, 2025 | -15.77% |
| Dec 31, 2024 | 13.83% |
| Sep 30, 2024 | 46.24% |
| Jun 30, 2024 | -192.53% |
| Mar 31, 2024 | 201.94% |
| Dec 31, 2023 | 124.52% |
| Sep 30, 2023 | 80.52% |
| Jun 30, 2023 | -75.20% |
| Mar 31, 2023 | 115.35% |
| Dec 31, 2022 | -131.02% |
| Sep 30, 2022 | -143.59% |
| Jun 30, 2022 | 205.78% |
| Mar 31, 2022 | -27.34% |
| Dec 31, 2021 | -171.07% |
| Sep 30, 2021 | 134.28% |